MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets

MannKind Corporation (NASDAQ:MNKD) is among the best NASDAQ penny stocks to buy according to analysts. On 26 February, MannKind Corporation (NASDAQ:MNKD) shared its plans at the Oppenheimer healthcare conference. The company said it expects strong growth from its main products. These include Afrezza for children, the FUROSCIX autoinjector, and a new drug program, MNKD-201, for lung disease (IPF). Even though there may be competition from United Therapeutics, MannKind’s leaders said they feel positive about the future.

The company hopes to exceed $450 million in revenue by 2026. It expects growth from Afrezza, FUROSCIX, and royalties from Tyvaso DPI. The company also believes it could receive $700 million to $1 billion in cash from Tyvaso over the next few years.

Afrezza may soon be approved for children, with a decision expected on May 29. The company is also testing a smaller dose to make it easier for kids to use. FUROSCIX is expected to grow, especially in hospitals, and the new autoinjector could help sales. MNKD-201 is now in early studies, and more results are expected later this year.

On the same day, MannKind Corporation reported Q4 2025 revenues of $112 million, up 46% from the prior year, with Furoscix and Afrezza each contributing $23 million in sales. Full-year 2025 revenue reached $349 million, a 22% increase, boosted by the acquisition of scPharmaceuticals.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on improving care for chronic diseases.,It develops and sells treatments for serious health needs such as diabetes, pulmonary hypertension, and heart failure. The company also works on therapies for fluid overload in chronic kidney disease.

While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Italian Stocks to Buy in 2026.

Disclosure: None.  Follow Insider Monkey on Google News.